213Bi-9E7.4

213Bi-9E7.4 is an experimental radiopharmaceutical designed for the treatment of multiple myeloma. It is a radioimmunoconjugate composed of the monoclonal antibody 9E7.4, which specifically targets the CD138 (Syndecan-1) antigen, and the alpha-emitting radionuclide Bismuth-213 (213Bi). CD138 is a hallmark surface marker for plasma cells and is highly overexpressed in multiple myeloma. The 9E7.4 antibody serves as a delivery vehicle, bringing the 213Bi isotope into close proximity with the tumor cells. Bismuth-213 decays by emitting alpha particles, which possess high linear energy transfer (LET) and a short path length (50-80 µm), resulting in dense ionization and potent cytotoxic effects, primarily through the induction of irreparable double-strand DNA breaks. This targeted approach aims to maximize tumor cell killing while minimizing damage to surrounding healthy tissues. The agent has been extensively studied in preclinical murine models, such as the 5T33 model, to demonstrate the superior efficacy of alpha-radioimmunotherapy over beta-emitting alternatives.

Other names

213Bi-anti-mCD138Bismuth-213-9E7.4Bismuth213-9E7.4Bismuth 213-9E7.4Bismuth-213-labeled anti-CD138 antibodyBismuth213-labeled anti-CD138 antibodyBismuth 213-labeled anti-CD138 antibody